Literature DB >> 15164249

Carbohydrate-electrolyte (E-Lyte) solution enhances bowel preparation with oral fleet phospho-soda.

Joe J Tjandra1, Peter Tagkalidis.   

Abstract

PURPOSE: Bowel preparation with oral sodium phosphate can cause symptomatic dehydration and electrolyte disturbances. This randomized, controlled trial was designed to evaluate whether carbohydrate-electrolyte (E-Lyte) solution enhanced bowel preparation and improved patient acceptance with oral sodium phosphate.
METHODS: A total of 187 consecutive adults undergoing colonoscopy by two endoscopists were randomized to receive two packets of oral sodium phosphate (Fleet Phospho-soda) with or without additional supplement of a carbohydrate-electrolyte (E-Lyte) solution. All patients and endoscopists completed a standardized questionnaire. Urine-specific gravity and serum biochemistry were randomly performed in 150 and 50 patients, respectively.
RESULTS: Ninety patients were randomized to have oral sodium phosphate with E-Lyte supplements (Group 1) and 94 patients to sodium phosphate without E-Lyte supplements (Group 2). The groups were similar in age and gender, indication for colonoscopy, and previous colonic surgery. Patients taking E-Lyte supplement had significantly less dizziness (none, 80 vs. 56 percent; P < 0.001) and a trend toward less nausea (none, 70 vs. 56 percent; P = 0.05). All patients in Group 1 completed the bowel preparation as opposed to 3 percent of Group 2 being unable to complete the preparation. Hypokalemia was significantly more frequent ( P = 0.008) in Group 2 patients without E-Lyte supplements. More patients in Group 2 needed intravenous rehydration (11 vs. 4 percent). Differences in serum creatinine and urine-specific gravity suggested possibly a lesser degree of hypovolemia in patients taking E-Lyte supplements. The quality of bowel cleansing in patients taking E-Lyte supplements was considered better by both the endoscopists and patients.
CONCLUSIONS: Carbohydrate-electrolyte (E-Lyte) solution protects against hypokalemia, improves patient tolerability, and may enhance use of oral sodium phosphate as a bowel-preparation agent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164249     DOI: 10.1007/s10350-004-0559-2

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

Review 1.  Commonly used preparations for colonoscopy: efficacy, tolerability, and safety--a Canadian Association of Gastroenterology position paper.

Authors:  Alan Barkun; Naoki Chiba; Robert Enns; Margaret Marcon; Susan Natsheh; Co Pham; Dan Sadowski; Stephen Vanner
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

2.  A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).

Authors:  Steven D Wexner; David E Beck; Todd H Baron; Robert D Fanelli; Neil Hyman; Bo Shen; Kevin E Wasco
Journal:  Surg Endosc       Date:  2006-06-08       Impact factor: 4.584

3.  Polyethylene glycol vs. sodium phosphate for bowel preparation: a treatment arm meta-analysis of randomized controlled trials.

Authors:  Ravi Juluri; George Eckert; Thomas F Imperiale
Journal:  BMC Gastroenterol       Date:  2011-04-14       Impact factor: 3.067

Review 4.  Oral colorectal cleansing preparations in adults.

Authors:  Sherief Shawki; Steven D Wexner
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Optimal and safe bowel preparation for colonoscopy.

Authors:  Won Moon
Journal:  Clin Endosc       Date:  2013-05-31

6.  A Comparative Clinical Study of a Novel Pre-colonoscopy Bowel Capsule Preparation Against Two Commercially Available Liquid Preparations.

Authors:  Harriet Kingston-Smith; Anoja W Gunaratne; John Saxon; Sanjay Ramrakha; Marie Vic M Dawson; Annabel Clancy; Antony Wettstein; Thomas J Borody
Journal:  Front Med Technol       Date:  2021-02-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.